About us

Michał Walczak is a Chief Executive Officer, Chief Scientific Officer, responsible for R&D and strategy. He obtained a PhD degree from the Swiss Federal Institute of Technology in Zurich, ETH Zurich, and studied at the University of Wroclaw and University of Virginia. He completed his postdoctoral training at the Friedrich Miescher Institute for Biomedical Research in Basel, which is a part of Novartis Institutes for Biomedical Research. 

Chief Operating Officer at Captor Therapeutics. Ph.D. in Biochemistry from the University of Wroclaw and Executive MBA from WSB Wroclaw University. Having 20 years of R&D experience, she is responsible for day-to-day operations, overseeing the implementation of optimal processes, standards, and solutions to help the business run smoothly. In her role she has the opportunity for continuous development, and solving daily challenges gives her a lot of satisfaction. As for hobbies, she is an avid traveller and book lover.

Chief Financial Officer. Joined Captor Therapeutics after working for almost 20 years on the capital market. Adam previously was the head of the team that managed equity mutual funds at TFI Allianz Polska; worked also, among other companies, for Skarbiec TFI and Credit Suisse Asset Management. Adam graduated from Wrocław University of Economics (financial management) and received PhD from Kozminski University in Warsaw (management and quality sciences). Adam earned several licences and certificates including: the investment adviser licence, the Chartered Financial Analyst charter, and certificates in: management accounting, risk management and managing alternative investments. In his spare time enjoys reading books, playing games (video and board) and gardening.

Co-founder and SVP Chemistry at Captor Therapeutics who builds scientific strategy and oversees chemistry efforts. Prior to Captor, served as Global Head at Center for Proteomic Chemistry at Novartis Institutes for Biomedical Research, where he played key roles in multiple successful discovery and development programs, e.g. Afinitor^TM and in-licensing of Gilenya^TM. He studied and received PhD in organic chemistry from EPFL Lausanne. In his free time he enjoys cycling and travelling.

Chief Medical Officer at Captor Therapeutics. Physician, specialist in Internal Medicine and Clinical Oncology, with over 30 years of clinical experience in patient care and systemic treatment of solid tumors. For many years, he led the Department of Clinical Oncology at a large regional hospital in Poland, while also serving as the hospital’s Medical Director. Clinical research specialist with extensive experience in the management of both small preclinical and translational studies in animal models, as well as, predominantly, Phase I–IV clinical trials, acting as Medical Director and Medical Consultant. He also has experience in preclinical and clinical research of medical devices in oncology. His clinical interests primarily include the treatment of breast cancer, lung cancer, and gastrointestinal malignancies, oncology immunotherapy, genitourinary cancers, metronomic chemotherapy across various indications, and novel therapeutic approaches in oncology. Member ASCO, ESMO, SITC, TIP, PTOK. He has also participated in independent international expert panels evaluating the safety of novel oncology therapies.

Marta Tomaszewska is VP of People and Culture at Captor Therapeutics. She is a graduate of Wroclaw University of Economics and SWPS University. She has nearly 20 years of professional experience in HR in Polish and foreign companies. She implements HR tools and development projects including recruitment, onboarding, talent management, competence development, and employee engagement building. Supports the Management Board and Managers in making business decisions. Values active recreation, travel, time spent with loved ones, and moments on the mat with yoga.

VP of Biology at Captor Therapeutics, where he oversees and coordinates the preclinical development of compounds, including translational studies. He obtained Ph.D. in Molecular and Cellular Biology from the University of Cologne, Germany. With over 30 years of experience in this field, he has held leadership positions and managed projects, teams, and departments in both large pharmaceutical and small biotech companies, primarily in the United States. He has led the development of several novel drug candidates that have entered clinical evaluation, focusing on both oncology and immune diseases. Outside of work, he is passionate about skiing and mountain biking.

30 years’ experience of Biotech senior management in the UK, USA, France, Switzerland, Australia and Poland, leading 12 major license agreements, 6 private investor rounds and 3 IPOs.
Awarded a PhD in biochemistry from Strathclyde University, Glasgow, and CEP diploma from the London Business School. Keen amateur musician and enjoys hiking, sailing, skiing and photography.

Member of the Scientific Advisory Board at Captor Therapeutics. Obtained a medical degree from Trinity College Dublin in 1989 and has practiced in haemato-oncology for over 30 years in both clinical practice and the pharmaceutical industry. Previous positions include CMO at oncology biotech’s including most recently RedX pharma (U.K.) and Lytix Biopharma Inc (Norway) and oncology drug development roles at Roche and Eli Lilly. Dr. Saunders has acted as an oncology consultant for multiple pharma/biotech companies and holds a diploma in Pharmaceutical Medicine and is a fellow of the Royal College of Physicians, United Kingdom. 

Chair of the Scientific Advisory Board, Prof. Dr. Galle majored in internal medicine at the Universities of Berlin, Marburg, Mannheim and Heidelberg, Germany, at Hammersmith Hospital, London/UK and, as a Fulbright grantee at University of Texas/USA and received his M.D. degree from Marburg University and Ph.D. degree from Heidelberg University. Initially he held a position as postdoctoral fellow in Molecular Biology at the Centre for Molecular Biology Heidelberg working on the replication of hepatitis B viruses. Afterwards he completed his residency in Internal Medicine and Gastroenterology at the University Hospital of Heidelberg. In 1998 he became Director of the I. Medical Department in Mainz and from 2005 – 2008 he hold the CEO position of Mainz University Hospital. He is member of several national and international societies such as the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), served as Co-editor for the Journal of Hepatology and was on the Editorial Boards of several other Journals. He served as congress president of the German Society for Digestive Diseases (DGVS) in 2014. He was member of the Executive Board and President of the International Liver Cancer Association (ILCA). He was the President of the German Association for the Study of the Liver (GASL) for the year 2020. His research has focused on elucidating important aspects of apoptotic cell death in the liver, immune escape of tumour cells and on clinical and molecular aspects of hepatocellular carcinoma (HCC). He chaired the panel updating the EASL Clinical Practice Guideline on HCC, which appeared in 2018. He was awarded several prizes, amongst others the prestigious Tannhauser award, the highest prize of the German Society for Digestive Diseases. In 2024 he received the Blue Faery Award for Excellence in Liver Cancer Research. He has published more than 550 peer-reviewed papers.